Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 84
Filter
1.
Rev. colomb. reumatol ; 29(2): 137-144, Apr.-June 2022. tab
Article in English | LILACS | ID: biblio-1423917

ABSTRACT

ABSTRACT HTLV-1 is a retrovirus that has an impact on human health due to its T-lymphocyte tropism. It occurs worldwide, but is more prevalent in tropical regions. Although most infected individuals will remain asymptomatic, the infection may manifest with complications such as uveitis, myelopathy, and leukemia, among others. The diagnosis is a chieved by the detection of anti-HTLV antibodies and a confirmatory test (Western Blot or proviral load). Although there is no specific treatment, medical treatments are aimed towards the management of secondary diseases. Three cases are described of pediatric patients diagnosed with HTLV-1 infection and associated autoimmune manifestations.


RESUMEN El virus linfotrópico humano de células T tipo I (HTLV-1) es un retrovirus que causa impacto en la salud del ser humano debido al tropismo para infectar a linfocitos T. Está distribuido mundialmente, pero es más prevalente en regiones tropicales. La mayoría de las personas afectadas permanecen asintomáticas, sin embargo, al manifestarse puede causar complicaciones como uveítis, mielopatía y leucemia, entre otras. Su diagnóstico se hace mediante la determinación de anticuerpos anti-HTLV y prueba confirmatoria (Western Blot o carga proviral). No tiene tratamiento específico, las medidas están dirigidas a la prevención y el manejo de las afecciones secundarias. Se describen tres pacientes en edad pediátrica con diagnóstico de infección por HTLV-1 y manifestaciones autoinmunes.


Subject(s)
Humans , Infant , Child , Oncogenic Viruses , Retroviridae , Viruses , Human T-lymphotropic virus 1 , Inflammatory Bowel Diseases , Crohn Disease , Digestive System Diseases , Gastrointestinal Diseases
2.
DST j. bras. doenças sex. transm ; 34: 1-9, fev. 02, 2022.
Article in English | LILACS | ID: biblio-1402110

ABSTRACT

Human Papillomavirus (HPV) infection is the most common sexually transmitted infection in women. About 80% of sexually active women will have contact with this virus at some point in their lives. Most infections will be transient, but when the infection becomes persistent and associated with a high oncogenic risk of Human Papillomavirus, there may be progression to cancer, especially cervical cancer. The best way to prevent Human Papillomavirus infection is through the use of vaccines, which have been available to the public in Brazil since 2014. Objective: This study aimed to assess the most prevalent types of Human Papillomavirus in the state of Santa Catarina, Brazil, and its mesoregions and if the majority of diagnosed types are contained in the Human Papillomavirus vaccines currently available on the market. Methods: A total of 20,000 Human Papillomavirus tests were evaluated for the diagnosis of genital Human Papillomavirus infection in women from the state of Santa Catarina, Brazil. The prevalence of infection was evaluated according to age and the city of origin of the exams. Human Papillomavirus detection was performed using molecular biology tests, such as hybrid capture (for diagnosis of the Human Papillomavirus group, high or low oncogenic risk) and polymerase chain reaction (viral genotyping) techniques. Results: The diagnosis of Human Papillomavirus infection was performed on women between 1 and 102 years of age. The age with the highest Human Papillomavirus positivity, as expected, was 20­25 years (45.6%) and the lowest after 70 years (7.1%). The highest Human Papillomavirus positivity of the exams was observed in the Serrana region of Santa Catarina state (58.9% of the exams). A high-oncogenic-risk Human Papillomavirus was detected in 93% of positive samples and was the most frequent in all age groups. Mixed infection (high- and low-risk Human Papillomavirus) was more prevalent in the 66­70 age group (29.3%) and in the Southern Region of Santa Catarina (26.4%). The most frequent genotypes in the state of Santa Catarina were non-16/18 high oncogenic risk Human Papillomavirus (76.9% of positive cases). Human Papillomavirus 16 was found in 17.1% of positive cases and Human Papillomavirus 18 in 6.6%. Conclusion: The most prevalent types of Human Papillomavirus in the state of Santa Catarina in the past 6 years are the non-16/18 high oncogenic risk Human Papillomavirus types, which are viral types not covered by the current Human Papillomavirus vaccines available in Brazil.


A infecção por Papilomavírus Humano é a infecção sexualmente transmissível mais frequente na mulher. Cerca de 80% das mulheres sexualmente ativas entrarão em contato com esse vírus em algum momento. A maioria das infecções será transitória, mas quando ela é persistente, associada aos Papilomavírus Humano de alto risco oncogênico, poderá progredir para câncer, principalmente de colo de útero. A melhor forma de se prevenir da contaminação pelo vírus é por meio de vacina, disponível no sistema público do Brasil desde 2014. Objetivo: Avaliar os tipos de Papilomavírus Humano mais prevalentes no estado de Santa Catarina e suas mesorregiões, e se a maioria dos tipos diagnosticados estão contidos nas vacinas contra o Papilomavírus Humano atualmente disponíveis no mercado. Métodos: Foram avaliados 20 mil exames para diagnóstico da infecção genital pelo Papilomavírus Humano em mulheres de todo o estado. A prevalência da infecção foi comparada de acordo com a idade e a procedência dos exames. A detecção do Papilomavírus Humano deu-se pelos exames de biologia molecular pelas técnicas de captura híbrida (para diagnóstico do grupo de Papilomavírus Humano, alto ou baixo riscos oncogênicos) e de PCR (genotipagem viral). Resultados: Foram avaliados exames para diagnóstico da infecção de mulheres entre um e 102 anos de idade. A faixa etária de maior positividade, como era de ser esperado, foi dos 20 aos 25 anos (45.6%) e a menor depois dos 70 anos (7.1%). A maior positividade dos exames foi observada na região Serrana do estado (58.9% dos exames). O Papilomavírus Humano de alto risco oncogênico foi detectado em 93% dos casos positivos e foi o mais frequente em todas as faixas etárias. A infecção mista (Papilomavírus Humano de alto e baixo riscos) foi mais prevalente na faixa etária dos 66 aos 70 anos (29.3%) e na região Sul Catarinense (26.4%). Os genótipos mais frequentes no estado foram os Papilomavírus Humano de alto risco oncogênico não 16/18 (76.9% dos casos positivos). O Papilomavírus Humano 16 foi encontrado em 17.1% dos casos positivos e o Papilomavírus Humano 18 em 6.6%. Conclusão:Os tipos de Papilomavírus Humano mais prevalentes no estado de Santa Catarina, nos últimos seis anos, são os Papilomavírus Humano de alto risco oncogênico não 16/18, tipos virais não cobertos pelas atuais vacinas contra o Papilomavírus Humano disponíveis no Brasil.


Subject(s)
Humans , Alphapapillomavirus , Papillomavirus Vaccines , Reproductive Tract Infections , Oncogenic Viruses , Sexually Transmitted Diseases , Cervix Uteri
3.
Journal of Gynecologic Oncology ; : 20-2020.
Article in English | WPRIM | ID: wpr-811214

ABSTRACT

OBJECTIVE: The causal association of human papillomavirus (HPV) in uterine cervical cancer was well established and this oncogenic virus was reported to be a biomarker for overall recurrence and central pelvic recurrence. The objective of the present systematic review and meta-analysis was to assess the role of HPV DNA testing in early detection of recurrence among cervical cancer survivors after radiotherapy.METHODS: We performed a systematic review and meta-analysis by means of searching electronic databases for published articles between January 1984 and June 2018, on the basis of standard systematic review guidelines prescribed by major agencies namely Cochrane Collaboration (https://www.cochrane.org) and Campbell Collaboration (https://www.campbellcollaboration.org). The meta-analysis component was further modified appropriately for the synthesis of sensitivity and specificity results.RESULTS: A total of 1,055 cervical cancer cases who had received pelvic radiation with or without chemotherapy from ten cohort studies were evaluated. The overall pooled sensitivity and specificity of HPV DNA testing was 0.84 (95% confidence interval [CI]= 0.66–0.94) and 0.35 (95% CI=0.20–0.54) respectively. The positive likelihood ratio was 1.3 (95% CI=1.0–1.7) and the negative likelihood ratio was 0.45 (95% CI=0.18–1.10) with an estimated diagnostic odds ratio of 3 (95% CI=1–9).CONCLUSION: The screening for HPV DNA testing during follow-up facilitates early detection of recurrence after radiotherapy.


Subject(s)
Female , Humans , Cervix Uteri , Cohort Studies , Cooperative Behavior , DNA , Drug Therapy , Follow-Up Studies , Human Papillomavirus DNA Tests , Mass Screening , Odds Ratio , Oncogenic Viruses , Radiotherapy , Recurrence , Sensitivity and Specificity , Survivors , Uterine Cervical Neoplasms
4.
Rev. cuba. med. mil ; 47(1): 58-72, ene.-mar. 2018. tab
Article in Spanish | LILACS, CUMED | ID: biblio-960598

ABSTRACT

El cáncer se ha convertido en la primera causa de morbimortalidad en numerosos países. En las últimas décadas se ha asistido a un cambio en el paradigma conceptual de las enfermedades neoplásicas, que ahora se enfoca hacia la perspectiva ecológica-evolutiva de estas. Con el objetivo de analizar, con elementos actualizados, la relación entre el proceso evolutivo del ser humano y su predisposición al cáncer, se realizó una revisión sistemática de la literatura, a partir de tres bases de datos, Medline, Scopus, y SciELO. Se tuvieron en cuenta atributos de consistencia de los artículos revisados, se excluyeron los estudios con niveles IV y V de evidencia y los de calidad insuficiente. Las búsquedas acumuladas actuales sugieren la necesidad de ver a las diversas neoplasias desde la perspectiva de la dinámica de sistemas complejos y sus implicaciones evolutivas. El proceso evolutivo humano posee particularidades biosociales que le predisponen a sufrir tumores malignos. La postura bípeda incrementó vulnerabilidad al efecto oncogénico de las radiaciones ultravioletas. La conducta sexual incrementó el riesgo de contraer infecciones por virus oncogénicos. El paso a una predominantemente cárnica y la introducción de la cocción, se tradujo en la incorporación de agentes xenobióticos cuyo metabolismo deriva agentes carcinógenos. La postergación del envejecimiento humano devino en un mayor tiempo para el acúmulo de mutaciones. Las modificaciones en el patrón sexual y reproductivo en la mujer han influido en su predisposición al cáncer de mama. En la génesis poblacional del cáncer subyacen fundamentos biosociales vinculados al proceso evolutivo de la especie(AU)


Cancer has become the leading cause of morbidity and mortality in many countries. In recent decades there has been a change in the conceptual paradigm of neoplastic diseases, which now focuses on the ecological-evolutionary perspective of these. With the aim of analyzing, with updated elements, the relationship between the evolutionary process of the human being and his predisposition to cancer, a systematic review of the literature was made, based on three databases, Medline, Scopus, and SciELO. Consistency attributes of the reviewed articles were taken into account, studies with levels IV and V of evidence and those of insufficient quality were excluded. The current accumulated searches suggest the need to see the various neoplasms from the perspective of the dynamics of complex systems and their evolutionary implications. The human evolutionary process has biosocial peculiarities that predispose it to suffer malignant tumors. Bipedal posture increased vulnerability to the oncogenic effect of ultraviolet radiation. Sexual behavior increased the risk of contracting oncogenic virus infections. The transition to a predominantly meat and the introduction of cooking, resulted in the incorporation of xenobiotic agents whose metabolism derives carcinogens. The postponement of human aging became in a longer time for the accumulation of mutations. Modifications in the sexual and reproductive pattern in women have influenced their predisposition to breast cancer. In the population genesis of cancer underlying biosocial foundations linked to the evolutionary process of the species(AU)


Subject(s)
Humans , Oncogenic Viruses/physiology , Biological Evolution , Neoplasm Staging/mortality , Review Literature as Topic , Databases, Bibliographic
5.
Arq. bras. med. vet. zootec ; 68(6): 1602-1608, nov.-dez. 2016. tab, ilus
Article in English | LILACS, VETINDEX | ID: biblio-827951

ABSTRACT

Marek's disease (MD) is a lymphoproliferative disorder caused by Gallid herpesvirus 2 (MDV) that infects mainly domestic gallinaceous birds although wild birds may occasionally be affected. The current report describes the anatomopathological and molecular findings of a case of MD in a white-peafowl (Pavo cristatus). The signs included apathy, hyporexia, and diarrhea. Grossly, 0.5 to 1.5cm in diameter, yellow, soft nodules were observed in the skeletal muscle, lung, kidney, air sacs, small intestine, heart, ovary, ventriculus, and proventriculus. Microscopically, numerous atypical round neoplastic cells were noted. The molecular detection of MDV DNA was implemented to amplify part of the meq gene and products were sequenced for the phylogenetic analysis. Template DNA was obtained from tissues of the affected bird and from blood of all the gallinaceous birds of the Zoo. The expected amplicon for the partial amplification of MDV meq gene was obtained and the amplicons were sequenced. Sequences obtained enabled grouping the strain (accession no. KT768121) with MDV serotype 1 strains from the GenBank. Based on the anatomopathological and molecular findings, the diagnosis of MD in a white-peafowl was reached, and to the authors' knowledge, no previous report regarding MD was published in Pavo cristatus.(AU)


Doença de Marek (MD) é uma desordem linfoproliferativa causada pelo Gallid herpesvirus 2 (MDV), que infecta principalmente galináceos domésticos, porém aves silvestres podem ser ocasionalmente afetadas. O presente relato descreve os achados anatomopatológicos e moleculares de um caso de MD em um pavão-branco (Pavo cristatus). Os sinais clínicos incluíram apatia, hiporexia e diarreia. Macroscopicamente, foram observados nódulos macios, de 0,5 a 1,5cm de diâmetro, no músculo esquelético, no pulmão, nos rins, nos sacos aéreos, no intestino delgado, no coração, no ovário, no ventrículo e no proventrículo. Microscopicamente, numerosas células redondas neoplásicas atípicas foram notadas. A detecção molecular do DNA do MDV foi implementada para amplificar parte do gene meq, e os produtos foram sequenciados para análise filogenética. DNA foi obtido de tecidos de aves afetadas e do sangue de todos os galináceos do zoológico. A esperada amplificação de parte do gene meq de MDV amplificado foi ampliada e sequenciada. As sequências obtidas permitiram o agrupamento da cepa (acesso KT768121) com cepas do sorotipo 1 de MDV do GenBank.. O diagnóstico de MD em pavão-branco foi obtido com base nos achados anatomopatológicos e moleculares e, pelo conhecimento dos autores, não há relatos anteriores publicados de MD em Pavo cristatus.(AU)


Subject(s)
Animals , Galliformes/virology , Herpesvirus 2, Gallid/isolation & purification , Marek Disease/diagnosis , Lymphoma/veterinary , Oncogenic Viruses
6.
Journal of Pathology and Translational Medicine ; : 442-450, 2016.
Article in English | WPRIM | ID: wpr-53508

ABSTRACT

BACKGROUND: Human papillomavirus (HPV) is a well-established oncogenic virus of cervical, anogenital, and oropharyngeal cancer. Various subtypes of HPV have been detected in 0% to 60% of breast cancers. The roles of HPV in the carcinogenesis of breast cancer remain controversial. This study was performed to determine the prevalence of HPV-positive breast cancer in Korean patients and to evaluate the possibility of carcinogenic effect of HPV on breast. METHODS: Meta-analysis was performed in 22 case-control studies for HPV infection in breast cancer. A total of 123 breast cancers, nine intraductal papillomas and 13 nipple tissues of patients with proven cervical HPV infection were tested by real-time polymerase chain reaction to detect 28 subtypes of HPV. Breast cancers were composed of 106 formalin-fixed and paraffin embedded (FFPE) breast cancer samples and 17 touch imprint cytology samples of breast cancers. RESULTS: The overall odds ratio between breast cancer and HPV infection was 5.43 (95% confidence interval, 3.24 to 9.12) with I2 = 34.5% in meta-analysis of published studies with case-control setting and it was statistically significant. HPV was detected in 22 cases of breast cancers (17.9%) and two cases of intaductal papillomas (22.2%). However, these cases had weak positivity. CONCLUSIONS: These results failed to serve as significant evidence to support the relationship between HPV and breast cancer. Further study with larger epidemiologic population is merited to determine the relationship between HPV and breast cancer.


Subject(s)
Humans , Breast Neoplasms , Breast , Carcinogenesis , Case-Control Studies , Nipples , Odds Ratio , Oncogenic Viruses , Oropharyngeal Neoplasms , Papilloma , Papilloma, Intraductal , Paraffin , Prevalence , Real-Time Polymerase Chain Reaction
7.
Epidemiology and Health ; : e2015047-2015.
Article in English | WPRIM | ID: wpr-721200

ABSTRACT

Korean women with a history of never smoking and with adenocarcinoma showed an increasing trend in lung cancer occurrence during 2002 to 2012. The two modifiable factors of never-smoker lung cancer in women are hormone and oncogenic virus infection. Based on previous studies, hormone replacement therapy (HRT) and human papillomavirus (HPV) infection might afford protection or be a risk factor, respectively. It is necessary to perform a pooled analysis of cohort studies to evaluate HRT and never-smoker lung cancer in women and a systematic review of case-control studies to determine the association between HPV infection and never-smoker lung cancer.


Subject(s)
Female , Humans , Adenocarcinoma , Case-Control Studies , Cohort Studies , Hormone Replacement Therapy , Lung Neoplasms , Lung , Oncogenic Viruses , Risk Factors , Smoke , Smoking
8.
Epidemiology and Health ; : e2015005-2015.
Article in English | WPRIM | ID: wpr-721186

ABSTRACT

OBJECTIVES: Although an expert review published in 2013 concluded that an association between human papillomavirus (HPV) infection and prostate cancer (PCa) risk had not yet been firmly established, a 2011 systematic review of 14 articles revealed an increased prevalence of HPV-16 DNA in PCa tissues. Another meta-analysis of the related articles is needed to evaluate the potential link between HPV infection and PCa risk. METHODS: A snowballing search strategy was applied to the previously cited articles in the above-mentioned expert review and systematic review. Additional articles selected for this meta-analysis should fulfill all following inclusion criteria: (a) evaluation of detected HPV-16 DNA in tissue samples and the PCa risk and (b) report of the HPV-16 prevalence in both cancer and control tissues. Estimated summary odds ratios (sOR) with 95% confidence intervals (CI) were calculated using fixed effect or random-effect models. RESULTS: Hand searching identified 16 new articles. The sOR of the total 30 articles indicated a significant HPV-16 infection-related increase in the PCa risk (sOR, 1.851; 95% CI, 1.353 to 2.532, I2=37.82%). CONCLUSIONS: These facts provide additional supportive evidence for a causal role of HPV-16 infection in prostate carcinogenesis. As the PCa incidence rates have increased rapidly in Asian countries, including Korea, during the last several decades, further studies of HPV-related PCa carcinogenesis may be necessary.


Subject(s)
Humans , Asian People , Carcinogenesis , DNA , Hand , Human papillomavirus 16 , Incidence , Korea , Odds Ratio , Oncogenic Viruses , Passive Cutaneous Anaphylaxis , Prevalence , Prostate , Prostatic Neoplasms , Risk Factors
10.
Rev. Fac. Cienc. Méd. Univ. Cuenca ; 32(1): 6-15, Abril 2014. tab, ilus
Article in Spanish | LILACS | ID: biblio-1005502

ABSTRACT

Objetivos: Determinar la prevalencia de los genotipos del papiloma virus de alto y bajo grado oncogénico; relacionar con los grupos de edad, con los genotipos que evitan las dos vacunas existentes y con los fatores de riesgo para cáncer cervical uterino. Metodología: Estudio epidemiológico, observacional, transversal. La muestra aleatorizada fue de 500 mujeres de la zona urbana de la ciudad de Cuenca. Se efecturaon dos tomas del cuello uterino. Se utilizó el método de reacción de cadena de polimerasa y el estudio citopatológico Papanicolaou. Resultados: La prevalencia de los genotipos del papiloma virus de alto grado oncogénico fue del 35.9% y para bajo grado el 14.3%. La prevalencia de las alteraciones citológicas, Papanicolaou, fue del 16%. Estas prevalencias fueron más frecuentes en los grupos de 30 a 39 años y 40 a 50 años. Por inferencia, la cobertura de la vacuna Cervarix sería del 8% y para el Gardasil del 13%. Fueron factores de riesgo los relacionados con el número y frecuencia de relaciones sexuales, número de compañeros sexuales. Conclusiones. La prevalencia de los genotipos fue alta y la cobertura de las vacunas baja.


OBJECTIVES. To determine the prevalence of papilloma virus genotypes of high and low oncogenic grade, to relate to age groups, with genotypes that avoid both existing vaccines and the risk factors for uterine cervical cancer. METHODS. Epidemiological, observational, cross-sectional study. The random sample was 500 women from the urban area of Cuenca city. Two samples of the cervix were taken. Polimeraza chain reaction method and cytopathology Papanicolaou study were used. RESULTS. The prevalence of papilloma virus genotypes of high oncogenic grade was 35,9% and 14,3% low oncogenic grade. The prevalence of cytologic abnormalities, Papanicolaou, was 16%. This prevalence was more frequent in the group of 30-39 years, and 40-50 years. By inference, the coverage of the Cervarix vaccine would be 8% and 13% for Gardasil. Risk factors were related to the number and frequency of intercourse and number of sexual partners. CONCLUSION. The prevalence of genotypes was high and the vaccine coverage was low.


Subject(s)
Humans , Female , Adult , Middle Aged , Papillomaviridae , Prevalence , Genotype , Oncogenic Viruses , Uterine Cervical Neoplasms , Risk Factors
11.
Korean Journal of Pathology ; : 43-49, 2014.
Article in English | WPRIM | ID: wpr-128032

ABSTRACT

BACKGROUND: Human papillomavirus (HPV) is an oncogenic virus in cervical cancer and most invasive carcinomas (ICs) are caused by HPV16 and 18. However, the roles and contributions of other uncommon and rare genotypes remain uncertain. METHODS: HPV genotypes were retrospectively assessed using an HPV DNA chip that can specify up to 32 HPV genotypes. We arbitrarily regarded genotypes accounting for less than 6% of the total as uncommon and rare genotypes. RESULTS: A total of 3,164 HPV-positive cases were enrolled. In groups 2A, 2B, 3, and unclassified HPV genotypes, 2.4% of cases with uncommon HPV genotypes (68, 26, 34, 53, 66, 69, 70, 73, 40, 42, 43, 44, 54, 55, 61, 62, 6, and 11) showed high grade squamous intraepithelial lesions and ICs. There were no HPV32- and 57-infected cases. CONCLUSIONS: We found that the uncommon and rare HPV genotypes may provide incremental etiologic contributions in cervical carcinogenesis, especially HPV68, 70, and 53. Further studies on these uncommon and rare HPV genotypes will be of importance in establishing the significance of genotypes in different regions, especially in planning a strategy for further vaccine development as well as follow-up on the effectiveness of the currently used vaccines.


Subject(s)
Female , Humans , Carcinogenesis , Cervix Uteri , Follow-Up Studies , Genotype , Oligonucleotide Array Sequence Analysis , Oncogenic Viruses , Retrospective Studies , Uterine Cervical Neoplasms , Vaccines
12.
Infection and Chemotherapy ; : 257-260, 2014.
Article in English | WPRIM | ID: wpr-116972

ABSTRACT

Diffuse large B cell lymphoma (DLBCL) is one of the most common acquired immune deficiency syndrome (AIDS)-defining malignancies among human immunodeficiency virus-infected patients, and rectal cancer has recently emerged as a prevalent non-AIDS-defining malignancy. We report a case of rectal squamous cell carcinoma that was metachronous with DLBCL in an HIV-infected patient who was receiving highly active antiretroviral therapy. The patient was diagnosed with DLBCL and showed complete remission after chemotherapy. Follow-up imaging showed increased uptake at the rectum, previously treated as lymphoma. Repeated biopsy was performed and squamous cell carcinoma of the rectum was reported. After concurrent chemoradiation therapy, curative resection was performed.


Subject(s)
Humans , Acquired Immunodeficiency Syndrome , Antiretroviral Therapy, Highly Active , Biopsy , Carcinoma, Squamous Cell , Drug Therapy , Follow-Up Studies , HIV , Lymphoma , Lymphoma, AIDS-Related , Lymphoma, B-Cell , Oncogenic Viruses , Rectal Neoplasms , Rectum
13.
Medicina (B.Aires) ; 73(6): 585-596, Dec. 2013. ilus, graf, tab
Article in Spanish | LILACS | ID: lil-708582

ABSTRACT

El cáncer cérvico-uterino (CCU), que está fuertemente asociado a la infección por virus papiloma humano de alto riesgo (VPH-AR), sigue siendo un problema de salud pública en Latinoamérica. El uso de la citología para la detección de lesiones pre-cancerosas no ha tenido mayor impacto en las tasas de incidencia y mortalidad del CCU, que aún se mantienen altas en la región. La disponibilidad de nuevas técnicas de tamizaje para la detección de lesiones pre-cancerosas y de vacunas altamente eficaces que previenen casi todas las lesiones relacionadas con los VPH-AR de alto potencial oncogénico VPH 16 y 18, en mujeres no expuestas previamente al virus brindan una gran oportunidad para la prevención del CCU. La detección de VPH-AR representa actualmente un valioso componente de las guías clínicas para el tamizaje, manejo y tratamiento del CCU y sus lesiones precursoras. Se han desarrollado estrategias metodológicas que detectan un amplio espectro de tipos de VPH-AR; sin embargo, solo un pequeño subgrupo de ellas ha documentado la validación clínica para cualquiera de las indicaciones habituales de la detección de estos virus. Las pruebas de VPH que no estén validadas y que no hayan demostrado confiabilidad, reproducibilidad y exactitud no deben ser usadas en el manejo clínico. Una vez incorporada una prueba de VPH en el laboratorio, es esencial que el procedimiento completo sea sometido a un continuo y riguroso control de calidad para evitar prácticas subóptimas, potencialmente dañinas. Este artículo discute los recientes progresos y el estado actual de estos métodos.


Cervical cancer (CC), which is strongly associated to high-risk human papillomavirus (hr-HPV) infection, continues being a significant health problem in Latin America. The use of conventional cytology to detect precancerous cervical lesions has had no major impact on reducing CC incidence and mortality rates, which are still high in the region. New screening tools to detect precancerous lesions became available, which provide great opportunities for CC prevention, as do highly efficacious HPV vaccines able to prevent nearly all lesions associated with HPV-16 and -18 when applied before viral exposure. Currently, hr-HPV testing represents an invaluable component of clinical guidelines for screening, management and treatment of CC and their precursor lesions. Many testing strategies have been developed that can detect a broad spectrum of hr-HPV types in a single assay; however, only a small subset of them has documented clinical performance for any of the standard HPV testing indications. HPV tests that have not been validated and lack proof of reliability, reproducibility and accuracy should not be used in clinical management. Once incorporated into the lab, it is essential to submit the whole procedure of HPV testing to continuous and rigorous quality assurance to avoid sub-optimal, potentially harmful practices. Recent progress and current status of these methods are discussed in this article.


Subject(s)
Female , Humans , Alphapapillomavirus/isolation & purification , Uterine Cervical Dysplasia/virology , Oncogenic Viruses/isolation & purification , Papillomavirus Infections/diagnosis , Uterine Cervical Neoplasms/prevention & control , Alphapapillomavirus/classification , Alphapapillomavirus/genetics , Argentina/epidemiology , Uterine Cervical Dysplasia/prevention & control , Early Detection of Cancer , Incidence , Mass Screening/methods , Molecular Diagnostic Techniques/standards , Oncogenic Viruses/pathogenicity , Papillomavirus Infections/epidemiology , Papillomavirus Vaccines/therapeutic use , Sensitivity and Specificity , Uterine Cervical Neoplasms/virology
14.
Bol. venez. infectol ; 24(1): 5-11, ene.-jun. 2013. tab, graf
Article in Spanish | LILACS | ID: lil-721095

ABSTRACT

Entre las enfermedades de transmisión sexual, el virus del papiloma humano (VPH) es la que tiene mayor prevalencia a nivel mundial. Esta infección puede tener o no efecto oncogénico sobre la célula infectada, pudiendo clasificarse de acuerdo al genotipo como de alto y bajo riesgo. El objetivo es identificar la prevalencia de genotipos oncogenes del virus de papiloma humano a nivel genital en mujeres que acuden a una consulta ambulatoria del estado carabobo. Estudio descriptivo, no experimental de tipo transversal. Se estudiaron 51 pacientes en un año, elaborándose un instrumento de recolección de datos. Se realizó genotipificación de las lesiones cervicales de VPH usando la extracción de los ácidos nucleicos aplicando el método BOOM, con sílica magnética, en el equipo MiniMag. Para la amplificación y detección molecular de los cinco tipos cancérigenos del VPH, 16, 18, 31, 33 y 45. Se aplicó la metodología NASBA (amplficación de ácidos nucleicos en tiempo real) en el NucliSENS EasyQ. Las pacientes estudiadas, se encontraban entre 18 y 53 años de edad. La totalidad de ellas presentaron cervicitis como diagnóstico macroscópico. La periodicidad de la evaluación ginecológica, fue irregular en el 31,4% de los casos. La distribución según los resultados: genotipo 45 (5,9%); genotipo 16 (2%); genotipo 16 asociado al 18 (2%); genotipo 33 (2%). El 11,9% de las muestras procesadas resultaron positivas, estas se distribuyen de manera homogénea siendo el genotipo 45 el más frecuente, con un porcentaje bajo de infección mixta.


Among the sexually transmitted diseases, human papiloma virus (HPV) is the most prevalent Worldwide. This infection may not have oncogenic effect on the infected cell, can be classifield according to genotype as high and low risk. To identify the prevalence of genotypes oncogenes of human papillomavirus genital level in women attending an outpatient clinic of carabobo state. Descriptive, not experimental transversal type. We studied 51 patients in one year, using a data collection instrument. Genotyping was performed HPV cervical lesions using the extraction of cucleic acids using the method BOOM, with silica magnetic MiniMag on the computer. For amplification and detection of the five molecular carcinogenic HPV, 16, 18, 31, 33 and 45. We use NASBA methodology (nucleic acid amplification in real time) in the NucliSENS EasyQ. The patients studied were between 18 and 53 years of age. All of them had cervicitis as macroscopic diagnosis. The periodic gynecological evaluation was irregular in 31.4% of the cases. According to the results: genotype 45 (5.9%), genotype 16 (2%), associated with the genotype 16 18 (2%), and genotype 33 (2%) were found. 11.9% of the processed samples were postive, these are distributed evenly 45 being the most prevalent genotype, with a low percentage of mixed infection.


Subject(s)
Humans , Adult , Female , Communicable Diseases , Genotype , Papillomavirus Infections/genetics , Oncogenic Viruses , Sexually Transmitted Diseases , Tumor Virus Infections
15.
J. bras. patol. med. lab ; 49(2): 109-114, Apr. 2013.
Article in English | LILACS | ID: lil-678238

ABSTRACT

Cancer-causing viruses are responsible for up to 20% of cancers with infectious etiology, representing a serious public health problem worldwide. Since the discovery of the first human cancer-causing virus, several others have been associated with neoplasias. Recent advances in technologies for the determination of genomic and proteomic profiles have resulted in the discovery and availability of tumor markers with potential application in the screening, diagnosis, prognosis and treatment of cancer. Therefore, laboratory medicine has stood out as a fundamental tool in the prevention and management of these diseases.


Os vírus causadores de câncer são responsáveis por até 20% dos cânceres de etiologia infecciosa, representando um grave problema de saúde pública em todo o mundo. Desde a descoberta do primeiro vírus causador de neoplasias em humanos, vários outros têm sido associados ao câncer. Recentes avanços nas tecnologias de determinação de perfis genômicos e proteômicos resultaram na descoberta e na disponibilização de marcadores tumorais com potencial aplicação no rastreamento, no diagnóstico, no prognóstico e no tratamento do câncer, destacando a medicina laboratorial como ferramenta fundamental na prevenção e no manejo dessas enfermidades.


Subject(s)
Laboratory Test , Biomarkers, Tumor , Oncogenic Viruses
16.
São Paulo; s.n; 2012. 190 p. ilus, tab, graf.
Thesis in Portuguese | LILACS, Inca | ID: lil-667408

ABSTRACT

Foram estudados 2693 casos de linfomas malignos de cinco instituições do estado de São Paulo, entre os anos 1954 a 2008. Dentre eles, 889 foram linfomas de Hodgkin (LH, 33%) e 1804 não Hodgkin (LNH, 67%). Objetivamos determinar a frequência de vírus linfotrópicos nos vários tipos de linfomas, em relação aos dados clinicopatológicos e aos períodos de diagnóstico. Os dados clínicos foram obtidos dos prontuários dos pacientes. A pesquisa dos vírus de Epstein Barr (EBV), humano tipo 8 (HHV8) e símio-40 (SV40) foi feita nos tecidos tumorais incluídos em parafina, através da imunoistoquímica e hibridização in situ (HIS). Dentre os dados anteriormente não explorados em nosso meio, destacaremos o que consideramos mais relevantes. O tipo esclerose nodular (ENOD) dos LH é o mais prevalente (68,2%), seguido da celularidade mista (CM; 21,8%). Houve um aumento da frequência do tipo ENOD nos períodos estudados: 61,2% em P1 (1954-1979), 69,2% em P2 (1980-1999) e 73,6% em P3 (2000-2008), porém sem significância. Apesar da alta frequência de relação dos LH com o EBV (46,9% na ENOD e 82,9% na CM), esta é significativamente mais alta em P1 (86,8% em todos os tipos) que em P2 (56,2%) e P3 (46,2%). No tipo ENOD, houve significativa redução da frequência de expressão de EBV nos três períodos, o que não ocorreu com a CM. Esta redução de relação com o EBV nos três períodos ocorreu na faixa etária estudada infanto-juvenil (menores de 15 anos) e de adultos (15-45 anos), mas não na de adultos maduros (com mais de 45 anos). A expressão de EBV esteve associada com sobrevida menos favorável apenas nas faixas inferiores aos 45 anos. Os LNH foram representados em sua maior parte pelos difusos de grandes células B (LDGCB; 56,7%), seguido pelos linfomas foliculares (LF; 19%). Os linfomas de células do manto, cuja frequência em nosso meio ainda não havia sido relatada em grande número de casos, foi semelhante à dos outros países ocidentais, ao redor de 5%...


Subject(s)
Humans , Multicenter Studies as Topic , Lymphoma , Oncogenic Viruses
17.
PAFMJ-Pakistan Armed Forces Medical Journal. 2009; 59 (2): 146-148
in English | IMEMR | ID: emr-92287
18.
Colomb. med ; 39(2): 196-204, abr.-jun. 2008. graf, tab
Article in Spanish | LILACS | ID: lil-573272

ABSTRACT

La vacuna profilßctica contra el virus del papiloma humano (VPH) constituye la herramienta de salud pública mßs promisoria para la prevención primaria de cßncer de cuello uterino. La vacunación de mujeres antes de haber adquirido la infección viral tiene un gran impacto en la prevención de lesiones pre- eoplßsicas y cßncer de cuello uterino. Las vacunas actuales no eliminan completamente el riesgo de cßncer de cérvix, por lo tanto las mujeres vacunadas como las que no alcancen a recibir la vacuna, se les debe seguir ofreciendo los programas de detección temprana. Las estrategias que incluyen la combinación de vacunación con alta cobertura de adolescentes y tamización con métodos mßs sensibles que la citología, tales como la prueba de VPH, pueden ser mßs costo-efectivas que las estrategias actualmente utilizadas. La inefectividad de los actuales programas de tamización en países latinoamericanos incluido Colombia, amerita su evaluación inmediata a la luz de la disponibilidad de nuevos métodos que son costo-efectivos en países en desarrollo tales como la prueba de VPH y la inspección visual y tratamiento inmediato para mujeres con dificultades de acceso oportuno al tratamiento.


Prophylactic human papillomavirus (HPV) vaccine is the most promissory public health tool for primary prevention of cervical cancer. Immunization of females before the acquisition of HPV infection has the greatest impact in preventing pre-neoplasic lesions and cervical cancer. Current HPV vaccines do not eliminate cervical cancer risk, therefore, screening should continue covering vaccinated as well as women that do not get the vaccine. The strategies that include combination of high-coverage vaccination of HPV-unexposed adolescents with screening using methods with higher sensitivity than cytology as HPV test may be more cost-effective than the strategies currently used. The cytology-based screening programs of Latin America countries including Colombia are very ineffective. The evidence in favor of the cost-effectiveness of other screening strategies such as HPV tests and visual inspection followed by immediate treatment for women with difficult access to health care services in developing countries warrants the immediate revision of the current strategies.


Subject(s)
Humans , Uterine Cervical Dysplasia , Condylomata Acuminata , Disease Prevention , Oncogenic Viruses , Papillomavirus Vaccines , Uterine Cervical Neoplasms , Vaginal Neoplasms , Vulvar Neoplasms , Warts
19.
Rev. venez. oncol ; 19(2): 135-141, abr.-jun. 2007. tab
Article in Spanish | LILACS | ID: lil-481071

ABSTRACT

La clínica músculo esquelética puede constituir manifestación de debut de muchos tumores. Pretendemos mostrar datos epidemiológicos relevantes que presentan pacientes diagnosticados de neoplasia en una sala de reumatología. Estudio retrospectivo longitudinal protocolizado de historiales de pacientes diagnosticados de neoplasia en el período 1996-1998. 653 ingresos en reumatología de 12 320 consultas externas en dicho período; 5 por ciento con diagnóstico de cáncer (2,7 por ciento del total). Media de edad de 69 años. Tiempo desde inicio de síntomas hasta diagnóstico: 2 a 6 meses en 80 por ciento de casos; clínica osteoarticular presentada: dolor inflamatorio en el esqueleto axial (12 casos; 36 por ciento) lumbalgia (7/ 21 por ciento), dorso-lumbalgia (2/0,6 por ciento), cervicobraquialgia (1/0,3 por ciento), raquialgia global (1/0,3 por ciento); poliartralgias de ritmo continuo (24 por ciento), coxalgia (4/0,12 por ciento), hombro doloroso (3/0,9 por ciento), escapulalgia (1/0,3 por ciento), síndrome polimiálgico en artritis reumatoide (2/0,6 por ciento) y dermatomiositis (1/0,3 por ciento). Tumores diagnosticados: mieloma (10 casos), carcinoma de próstata (9), tumores digestivos (2), pulmón (2), urogenitales (2), mama (1), leucemia (1), endometrio (1) metastáticos (5). Las proteínas C reactiva, y velocidad de sedimentación globular elevadas en el 90 por ciento de pacientes. 5 por ciento de pacientes ingresados en reumatología se diagnostican de cáncer. El perfil epidemiológico que presenta el paciente suele corresponder a adulto mayor de 60 años, con clínica de dolor inflamatorio axial o poliarticular con más de 2 meses de evolución, elevaciones de PCR y VSG suelen estar presentes en la mayoría de casos.


Subject(s)
Humans , Male , Female , Rheumatology , Inflammation , Oncogenic Viruses , Oncogenic Viruses , Spain , Medical Oncology
20.
Niterói; s.n; 2007. 141 p. graf, ilus, tab.
Thesis in Portuguese | LILACS | ID: lil-695537

ABSTRACT

A família dos papilomavírus (PV) representa um grupo heterogêneo de vírus. Até o momento mais de 120 tipos diferentes de papilomavírus humanos (HPV)já foram descritos. Os HPV isolados de uma mesma espécie são classificados ainda em subtipos. A associação entre o câncer e infecção pelo HPV no epitélio do trato genital masculino e feminino já é bem conhecida. Na mucosa oral, entretanto, é ainda controversa. Alguns estudos demonstram a presença viral e sua correlação com a carcinogênese bucal, enquanto outros estudos não consideram sua participação no câncer da cavidade bucal. A displasia epitelial é um marcador histológico de pré-malignidade e indica risco de evolução para Carcinoma de células escamosas...Observou-se que 37% das lesões não apresentavam displasia epitelial que ocorreu com maior frequência nos condilomas acuminados. Ao utilizar o anticorpo monoclonal anti p16 ink4a, não foram observados casos considerados positivos para esta proteína nas lesões estudadas. Pelo fato de haver uma tendência a se considerar a cura após a remoção cirúrgica das lesões papilomatosas orais, equivocadamente, a realização de exame histopatológico vem sendo muitas vezes dispensado. Através de nossos resultados podemos direcionar para a necessidade de divulgação da importância do exame histopatológico para avaliação do potencial oncogênico dos papilomas orais bem como a possível indicação de análise imunohistoquímica para diagnóstico definitivo em relação à presença de displasia epitelial.


Subject(s)
Humans , Carcinoma , DNA Probes, HPV , Mouth Neoplasms , Oncogenic Viruses , Cell Proliferation
SELECTION OF CITATIONS
SEARCH DETAIL